Agenda

Date and TimeTitle
Oct 27, 2022
8:30am - 9:15am (Central)
The Efficacy and Safety of ENHERTU

Sponsored by Daiichi Sankyo, Inc. & AstraZeneca

This is a Non CME/CE Presentation.

Oct 27, 2022
11:44am - 11:55am (Central)
Break: Explore the Virtual Conference Center
Oct 27, 2022
11:55am - 12:35pm (Central)
A First-Line CDK4/6 Inhibitor Combination Therapy: Clinical Trial Evidence Complemented by a Real-World Effectiveness Evaluation

This industry sponsored program will share evidence from routine clinical practice, which complements findings from the randomized clinical trials PALOMA-2 and PALOMA-3. Real-world data for HR+/HER2- aBC/mBC patients treated with CDK4/6 inhibitor combination therapy will also be evaluated. 

Sponsored by Pfizer

This is a Non CME/CE Presentation.

Oct 27, 2022
12:40pm - 12:55pm (Central)
Break: Explore the Virtual Conference Center
Oct 27, 2022
5:22pm - 6:00pm (Central)
Break: Explore the Virtual Conference Center
Oct 28, 2022
8:30am - 9:15am (Central)
Explore data for an FDA-approved treatment option in HR+, HER2- breast cancer in certain adjuvant or metastatic settings

PP-AL-US-2989 © Lilly USA, LLC 2021. All rights reserved. 

Sponsored by Lilly

This is a Non CME/CE Presentation.

Oct 28, 2022
11:50am - 12:28pm (Central)
A Targeted Adjuvant Therapy for Patients With gBRCAm, HER2-Negative, High-Risk Early Breast Cancer Who Have Been Treated With Neoadjuvant or Adjuvant Chemotherapy

Sponsored by AstraZeneca

This is a Non CME/CE Presentation.

Oct 29, 2022
7:15am - 7:57am (Central)
Consider TRODELVY® (sacituzumab govitecan-hziy) in 2L and Later mTNBC
This will be a branded promotional speaker program on TRODELVY® for physicians. The presenter will discuss key information for TRODELVY®.

Sponsored by Gilead

This is a Non CME/CE Presentation.

Dec. 09, 2022 - 9:01 am to Jan. 01, 2023 - 9:01 am (Central)Enduring - Session I: Breast Cancer Risk Assessment and Screening

9:00 am CT | Morning Welcome/Session I Introduction
Elizabeth A. Morris, MD

9:05 am CT | Individualized Breast Cancer Risk Assessment 
Heather Hampel, MS, CGC

9:35 am CT | Implications of Density in Breast Cancer Risk
Stamatia Destounis, MD, FACR

10:05 am CT | Clinical Application and Predictive Value of the Breast Imaging Reporting and Data System (BI-RADS®) 
Wendy DeMartini, MD

10:55 am CT | What’s New In Mammography?
Janice S. Sung, MD

11:25 am CT | Standard Mammography vs Breast MRI for Screening
Jessica W. T. Leung, MD

11:55 am CT | Screening Guidelines Panel
Elizabeth A. Morris, MD, Moderator
Wendy DeMartini, MD
Stamatia Destounis, MD, FACR
Heather Hampel, MS, CGC
Jessica W. T. Leung, MD
Janice S. Sung, MD

Supported by an independent educational grant from Bayer
Supported by an independent educational grant from Gilead Sciences, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 3.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Radiology Technologists
This activity will be submitted to the American Society of Radiologic Technologists (ASRT) for 3.0 hours of ARRT Category A continuing education credit.

Dec. 09, 2022 - 9:02 am to Jan. 01, 2023 - 9:02 am (Central)Enduring - Session II: PET Imaging and Beyond

1:05 pm CT | Session II Introduction
Elizabeth A. Morris, MD

1:10 pm CT | PET Imaging in Metastatic Breast Cancer 
Maxine S. Jochelson, MD

1:40 pm CT | Novel Strategies for Breast Cancer Assessment and Response 
Bonnie N. Joe, MD, PhD

2:10 pm CT | FES and FDG PET in ILC and IDC: Where Is the Clinical Impact?
Gary A. Ulaner, MD, PhD

3:00 pm CT | How Artificial Intelligence Is Changing Breast Imaging
Linda Moy, MD

3:30 pm CT | Precision Medicine and Radiogenomics: New Approaches for Diagnosis and Treatment of Breast Cancer 
Katja Pinker-Domenig, MD, PhD

4:00 pm CT | PET Imaging for Oncologists Panel
Maxine S. Jochelson, MD, Moderator
Katja Pinker-Domenig, MD, PhD
Bonnie N. Joe, MD, PhD
Linda Moy, MD
Gary A. Ulaner, MD, PhD

Supported by an independent educational grant from Bayer
Supported by an independent educational grant from Gilead Sciences, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 3.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Radiology Technologists
This activity will be submitted to the American Society of Radiologic Technologists (ASRT) for 3.0 hours of ARRT Category A continuing education credit.

Dec. 09, 2022 - 9:03 am to Jan. 01, 2023 - 9:03 am (Central)Enduring - Session III: Early Disease Considerations in HR-Positive Breast Cancer

9:30 am CT | Conference Welcome
Joyce Ann O'Shaughnessy, MD

9:35 am CT | Session III Introduction
Erika P. Hamilton, MD

9:40 am CT | Multidisciplinary Approach to Genomic Assays: What Have We Learned?
Sunil Badve, MD, FCRPath
Kevin Kalinsky, MD

10:10 am CT | Making Adjuvant Treatment Decisions Based on Risk of Recurrence in HR-Positive Early Breast Cancer
Joyce Ann O'Shaughnessy, MD
William Gradishar, MD

10:40 am CT | Test Your Knowledge: Clinical Considerations in the Treatment of Early HR-Positive Breast Cancer
Erika P. Hamilton, MD, Moderator
Sunil Badve, MD, FCRPath
Sarah Donahue, MPH, NP, AOCNP
William Gradishar, MD
Kevin Kalinsky, MD
Joyce Ann O'Shaughnessy, MD

11:10 am CT | Audience Q&A and Panel Discussion
Erika P. Hamilton, MD, Moderator
Sunil Badve, MD, FCRPath
Sarah Donahue, MPH, NP, AOCNP
William Gradishar, MD
Kevin Kalinsky, MD
Joyce Ann O'Shaughnessy, MD

Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Lilly
Supported by an independent educational grant from Gilead Sciences, Inc.
Supported by an independent educational grant from Seagen, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 2.0 contact hours and 0.200 CEUs. See individual session Universal Activity Number: JA0007105-0000-22-173-L01-P.

Dec. 09, 2022 - 9:04 am to Jan. 01, 2023 - 9:04 am (Central)Enduring - Session IV: Metastatic Disease Considerations in HR-Positive Breast Cancer

12:55 pm CT | Session IV Introduction
Erika P. Hamilton, MD

1:00 pm CT | A Remodeled Frontier in Metastatic HR-Positive Breast Cancer 
Seth A. Wander, MD, PhD

1:30 pm CT | A Review of Other Endocrine Agents in Advanced/Metastatic HR-Positive Breast Cancer
Erika P. Hamilton, MD

2:00 pm CT | Advanced/Metastatic HR-Positive Breast Cancer: CDK 4/6 Inhibitors and Beyond
Hope Rugo, MD
Jonathan W. Malara, PharmD, BCOP

2:30 pm CT | Audience Q&A and Panel Discussion
Erika P. Hamilton, MD, Moderator
Jonathan W. Malara, PharmD, BCOP
Hope Rugo, MD
Seth Wander, MD, PhD

Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Lilly
Supported by an independent educational grant from Gilead Sciences, Inc.
Supported by an independent educational grant from Seagen, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 2.0 contact hours and 0.200 CEUs. See individual session Universal Activity Number: JA0007105-0000-22-174-L01-P.

Dec. 09, 2022 - 9:05 am to Jan. 01, 2023 - 9:05 am (Central)Enduring - Session V: Special Topics in HR-Positive Breast Cancer

3:15 pm CT | Session V Introduction
Komal Jhaveri, MD

3:20 pm CT | ABCs of HR-Positive Breast Cancer: Review of PI3K- and AKT-Directed Therapies
Komal Jhaveri, MD

3:50 pm CT | Antibody-Drug Conjugates in HR-Positive Breast Cancer
Paolo Tarantino, MD
Jonathan W. Malara, PharmD, BCOP

4:20 pm CT | Managing Treatment Toxicities: Nursing and Pharmacist Perspectives
Kristina Byers, PharmD, BCOP
Sarah Donahue, MPH, NP, AOCNP

4:50 pm CT | Audience Q&A and Panel Discussion
Komal Jhaveri, MD, Moderator
Kristina Byers, PharmD, BCOP
Sarah Donahue, MPH, NP, AOCNP
Jonathan W. Malara, PharmD, BCOP
Paolo Tarantino, MD

Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Lilly
Supported by an independent educational grant from Gilead Sciences, Inc.
Supported by an independent educational grant from Seagen, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 2.0 contact hours and 0.200 CEUs. See individual session Universal Activity Number: JA0007105-0000-22-175-L01-P.

Dec. 09, 2022 - 9:06 am to Jan. 01, 2023 - 9:06 am (Central)Enduring - Session VI: Early Disease Considerations in HER2-Positive Breast Cancer

9:30 am CT | Morning Welcome & Session VI Introduction
Reshma L. Mahtani, DO

9:35 am CT | Optimizing Pre-Operative Treatment of HER2-Positive Breast Cancer
Reshma L. Mahtani, DO
Ana Garrido-Castro, MD

10:05 am CT | High-Risk Residual HER2-Positive Breast Cancer: Current and Future Directions (TDM1 and Beyond)
Ciara O'Sullivan, MD

10:35 am CT | Right-Sizing Therapy for HER2-Positive Breast Cancer
Nadine Tung, MD

11:05 pm CT | Audience Q&A and Panel Discussion
Reshma L. Mahtani, DO, Moderator
Ana Garrido-Gastro, MD
Ciara O'Sullivan, MD
Nadine Tung, MD

Supported by an independent educational grant from Daiichi Sankyo
Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Gilead Sciences, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 2.0 contact hours and 0.200 CEUs. See individual session Universal Activity Number: JA0007105-0000-22-176-L01-P.

Dec. 09, 2022 - 9:07 am to Jan. 01, 2023 - 9:07 am (Central)Enduring - Session VII: Metastatic Disease Considerations in HER2-Positive Breast Cancer

12:50 pm CT | Session VII Introduction
Reshma L. Mahtani, DO

12:55 pm CT | Treatment Sequencing for HER2-Positive Metastatic Breast Cancer
Alberto Montero, MD, MBA

1:25 pm CT | Emerging HER2-Directed ADCs for HER2-Positive Breast Cancer
A. Jo Chien, MD

1:40 pm CT | Novel TKIs, Bispecific Antibodies, and Immunotherapy
Paolo Tarantino, MD

1:55 pm CT | Mitigation and Management of Toxicities in HER2-Positive Breast Cancer: Nursing and Pharmacist Perspectives
Allison Butts, PharmD, BCOP
Jennifer McKenna, RN, MSN

2:25 pm CT | Audience Q&A and Panel Discussion
Reshma L. Mahtani, DO, Moderator
Allison Butts, PharmD, BCOP
A. Jo Chien, MD
Jennifer McKenna, RN, MSN
Alberto Montero, MD, MBA
Paolo Tarantino, MD

Supported by an independent educational grant from Daiichi Sankyo
Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Gilead Sciences, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 2.0 contact hours and 0.200 CEUs. See individual session Universal Activity Number: JA0007105-0000-22-178-L01-P.

Dec. 09, 2022 - 9:08 am to Jan. 01, 2023 - 9:08 am (Central)Enduring - Session VIII: Special Topics in HER2-Positive Breast Cancer

3:10 pm CT | Session VIII Introduction
Reshma L. Mahtani, DO

3:15 pm CT | How We Treat Brain Metastases in HER2-Positive Breast Cancer
Alexandra Zimmer, MD

3:45 pm CT | HER2 Status: Testing Today
Michael F. Press, MD, PhD

4:15 pm CT | HER2 Low: Where Are We?
Ian Krop, MD, PhD
Chau T. Dang, MD

4:45 pm CT | Audience Q&A and Panel Discussion
Reshma L. Mahtani, DO, Moderator
Chau T. Dang, MD
Ian Krop, MD, PhD
Michael F. Press, MD, PhD
Alexandra Zimmer, MD

Supported by an independent educational grant from Daiichi Sankyo
Supported by an independent educational grant from Exact Sciences

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 2.0 contact hours and 0.200 CEUs. See individual session Universal Activity Number: JA0007105-0000-22-178-L01-P.

Dec. 09, 2022 - 9:09 am to Jan. 01, 2023 - 9:09 am (Central)Enduring - Session IX: Early Disease Considerations in Triple Negative Breast Cancer

8:15 am CT | Morning Welcome/Session IX Introduction
Sara A. Hurvitz, MD

8:20 am CT | Updates on Systemic Therapy in Triple Negative Breast Cancer: Neoadjuvant/Adjuvant Therapies
Jennifer Litton, MD
Jonathan W. Malara, MD

9:00 am CT | Circulating Tumor DNA (ctDNA) and Minimal Residual Disease in Triple Negative Breast Cancer
Massimo Cristofanilli, MD, FACP
Denise Yardley, MD

9:30 am CT | Case Review: Testing Your Knowledge on Early Triple Negative Breast Cancer Management
Sara A. Hurvitz, MD, Moderator
Massimo Cristofanilli, MD, FACP
Jennifer Litton, MD
Jonathan Malara, MD
Denise Yardley, MD

10:00 am CT | Audience Q&A and Panel Discussion
Sara A. Hurvitz, MD, Moderator
Massimo Cristofanilli, MD, FACP
Jennifer Litton, MD
Jonathan Malara, MD
Denise Yardley, MD

Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Gilead Sciences, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 2.0 contact hours and 0.200 CEUs. See individual session Universal Activity Number: JA0007105-0000-22-179-L01-P.

Dec. 09, 2022 - 9:10 am to Jan. 01, 2023 - 9:10 am (Central)Enduring - Session X: Metastatic Disease Considerations in Triple Negative Breast Cancer

10:35 am CT | Session X Introduction
Sara A. Hurvitz, MD

10:40 am CT | Guideline-Based Standard Management of Metastatic Triple Negative Breast Cancer
Sara A. Hurvitz, MD

11:05 am CT | Novel Immunotherapy Strategies for Metastatic Triple Negative Breast Cancer
Rita Nanda, MD

11:30 am CT | New Non-IO Therapies in Triple Negative Breast Cancer: ADCs and Small Molecules
Neelima Vidula, MD

11:55 am CT | Brain Metastases: Systemic and Local Therapies
Carey K. Anders, MD

Priscilla Brastianos, MD

12:20 pm CT | Shared Decision-Making in Palliative Care
Lidia Schapira, MD

12:45 pm CT | Audience Q&A and Panel Discussion
Sara A. Hurvitz, MD, Moderator
Priscilla Brastianos, MD
Carey K. Anders, MD
Rita Nanda, MD
Lidia Schapira, MD
Neelima Vidula, MD

1:05 pm CT | Closing Remarks
Sara A. Hurvitz, MD

Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Gilead Sciences, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.5 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 2.5 contact hours and 0.250 CEUs. See individual session Universal Activity Number: JA0007105-0000-22-180-L01-P.